CS精准医

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

InnoCare Pharma's ICP-488 Completes First Patient Dosing in Phase II Trial for Cutaneous Lupus

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

AGEN

INGN

In the field of life sciences, innovation is crucial, but many companies continue to rely on inefficient workflows and manual tasks that consume valuable time. AINGENS CEO and founder Ome Ogbru, PharmD, highlights that the issue lies not in a lack of intelligence, but rather in the ineffective processes that are in place. These inefficiencies hinder progress and hinder experts from performing efficiently.

Unusual Whales

Agenus

Inogen

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

First Trust NYSE Arca Biotech Index Fd

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

Invesco Biotechnology & Genome ETF

Minsheng Royal CSI Biotechnology Theme ETF

SPDR S&P Health

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

VanEck Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Health Equip

Invesco Nasdaq Biotechnology ETF

Tianhong CNI BIOMEDICINE ETF

iShares US Medical Devices

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI All Share Health Care Devices ETF

Disrupting Scientific Friction: How Ome Ogbru Uses AI to Free Real Science

HCWC

AYRWF

A new study by The Wellness Company, led by Dr. Peter McCullough, shows that the off-label use of Ivermectin and Mebendazole has an 84% clinical benefit ratio in cancer treatment. Analyzing 197 patients, 48% reported cancer regression or no evidence of disease, while 36% experienced stability. The study highlights the need for further scientific investigation into these medications as potential cancer treatments, amidst growing distrust in the healthcare system. The Wellness Company offers a 90-day supply of these medications, emphasizing their safety and efficacy.

ZeroHedge

Healthy Choice Wellness

Wellness & Beauty Solutions Ltd.

Ayr Wellness Inc.

iShares Global Healthcare

iShares US Healthcare Providers

Health Care Select Sector SPDR

GROUNDBREAKING NEW STUDY REGARDING IVERMECTIN AND CANCER

Restore Hyper Wellness has declared May as NAD+ Month, launching exclusive offers to promote awareness and accessibility of NAD+ therapy. With a significant rise in consumer interest, the initiative aims to educate the public on the benefits of NAD+, a coenzyme crucial for cellular energy and health. The month features three offers, including discounted NAD+ IM shots and membership perks, to encourage participation in wellness routines. Dr. Rachele Pojednic emphasizes the long-term benefits of NAD+ supplementation for overall health.

prnewswire

Geratherm Medical AG

Alphabet

Alphabet - C

11:55 ETRestore Hyper Wellness Declares May NAD+ Month, Launching Exclusive Offers To Help Americans Recharge At The Cellular Level

BC Platforms has signed a Strategic Collaboration Agreement with AWS to enhance healthcare innovation and precision medicine. This partnership will leverage AWS technologies to improve BC Platforms' research environments, enabling global collaboration on real-world data and supporting the European Health Data Space (EHDS). The collaboration aims to accelerate the deployment of AI-powered analytical tools and provide secure, compliant data environments for healthcare organizations. BC Mosaic, BC Platforms' trusted research environment, will be available on AWS Marketplace, facilitating faster deployment and access to vital healthcare datasets.

Amazon

04:03 ETBC Platforms signs Strategic Collaboration Agreement with AWS to accelerate healthcare and life sciences innovation

003008

CS Analytical Laboratory has announced a major expansion of its Clifton, New Jersey facility, doubling its laboratory space to meet increasing client demands in the pharmaceutical, biotechnology, and medical device sectors. This expansion will enhance their capacity for innovative testing services, including raw materials testing and microbiological services, while also creating high-quality jobs. The facility is the only cGMP, FDA-registered contract laboratory dedicated to container testing, reinforcing its leadership in the industry.

Core Laboratories Luxembourg SA

KETOP

03:50 ETCS Analytical Announces Major Laboratory Expansion

513700

MintNeuro has partnered with Motif to integrate its neural sensing and stimulation chips with Motif's therapeutic implant platform. Announced on April 30, 2026, in London, this collaboration aims to enhance neuromodulation and enable real-time monitoring of responses, potentially revolutionizing neurotechnology and improving treatment options for various conditions.

Fidelity

Neurotech International Ltd.

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

BlackRock, Inc.

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

MintNeuro and Motif Neurotech Partner to Advance Miniature Brain-Computer Interface Therapy for Mental Health

CMND

ICUI

Artisight has recently secured a deal with UChicago Medicine in Chicago to roll out its Smart Hospital Platform throughout various care settings. The agreement involves installing over 1,800 devices in patient rooms, post-anesthesia care units (PACUs), and operating rooms. Additionally, the platform will be introduced to a new 575,000-square-foot freestanding cancer care facility, set to launch in April 2027. UChicago Medicine, a top academic health system in the country, is known for its comprehensive approach to clinical care.

Clearmind Medicine

ICU Medical

Prime Medicine

iShares US Pharma

Hwabao WP CSI Pharmaceuticals ETF

VG Health

Artisight Announces Agreement With UChicago Medicine to Deploy Smart Hospital Platform

Berlin Heals Holding AG announced positive results from its First-In-Human CMIC-III study, presented at the Heart Rhythm Society's Congress in Chicago. The study evaluated a novel, less invasive approach to implanting the cardiac microcurrent (CMIC) device, showing significant improvements in Left Ventricular Ejection Fraction (LVEF), 6 Minute Walk Test (6MWT), Quality of Life (QOL), and New York Heart Association (NYHA) class. The company is initiating Phase II of the study and launching the C-MIC-IV trial to expand patient access and gather critical data for FDA approval.

16:00 ETBerlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study

MIRA

miraDry, Inc. reported a 55% year-over-year growth in patient spend and a 43% increase in total treatments in Q1 2026, significantly outpacing the 4% growth of the broader aesthetic energy-based device market. This growth indicates strong patient demand, particularly among individuals over 35, who now make up nearly half of miraDry's patients. The company is launching Odor Awareness Week on April 20, 2026, featuring a webinar on odor science and patient trends. miraDry offers a non-surgical solution for excessive underarm sweat and odor, with over 500,000 patients treated globally.

Mira Pharmaceuticals

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Direxion S&P Biotech Bear 3X

Ark Genomic Revolution ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

iShares Biotechnology ETF

15:50 ETmiraDry® Reports 55% Growth in Patient Spend, Significantly Outpacing Aesthetic Energy-Based Device Market, and Kicks Off Odor Awareness Week

GNQ Insilico, a precision medicine TechBio company, has announced a collaboration with IBM to enhance the adoption of personalized medicine through its Causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms. This partnership aims to reduce clinical trial failure rates and improve treatment decisions by integrating IBM's consulting and hybrid cloud expertise. The platforms target emerging biopharma companies, large pharmaceutical organizations, and healthcare systems. GNQ has already secured a $96 million agreement to implement its Digital Twin Platforms across a North American health program, marking significant commercial momentum for the initiative.

fidelity

GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care

CS精准医(000863.SH)